<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39446477</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae491</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae491</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022-2023 influenza VE against illness and asymptomatic infection in a prospective cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription-polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September-October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 - adjusted hazard ratio) × 100%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%-55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: -47%, 49%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>White</LastName><ForeName>Elizabeth B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-9242-3507</Identifier><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8656-3538</Identifier><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9557-2690</Identifier><AffiliationInfo><Affiliation>Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsho</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4503-9745</Identifier><AffiliationInfo><Affiliation>Abt Associates, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0003-1579-2074</Identifier><AffiliationInfo><Affiliation>Abt Associates, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5747-4643</Identifier><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Jefferey L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-2362-9509</Identifier><AffiliationInfo><Affiliation>Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellingson</LastName><ForeName>Katherine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyner</LastName><ForeName>Harmony</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4130-0793</Identifier><AffiliationInfo><Affiliation>St. Luke's Regional Health Care System, Duluth, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaglani</LastName><ForeName>Manjusha</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3952-9230</Identifier><AffiliationInfo><Affiliation>Baylor College of Medicine, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutrick</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3480-849X</Identifier><AffiliationInfo><Affiliation>College of Medicine-Tucson, University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caban-Martinez</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5960-1308</Identifier><AffiliationInfo><Affiliation>University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newes-Adeyi</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4411-0370</Identifier><AffiliationInfo><Affiliation>Abt Associates, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duque</LastName><ForeName>Jazmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3484-276X</Identifier><AffiliationInfo><Affiliation>Abt Associates, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Sarang K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-8500-2886</Identifier><AffiliationInfo><Affiliation>University of Utah Health, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-2320-3567</Identifier><AffiliationInfo><Affiliation>University of Utah Health, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Westat, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britton</LastName><ForeName>Amadea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2684-8846</Identifier><AffiliationInfo><Affiliation>Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowlkes</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0620-6451</Identifier><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Marshfield Clinic Research Institute</Agency><Country /></Grant><Grant><Agency>University of Arizona</Agency><Country /></Grant><Grant><Agency>Abt Associates</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">asymptomatic infection</Keyword><Keyword MajorTopicYN="N">cohort</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">symptomatic illness</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>Potential conflicts of interest . A. N., L. J. E., J. D., H. T., G. N.-A., K. D. E., K. L., J. L. B., A. L. P., A. C.-M., and L. O. report funding from the CDC, Westat, or Abt Associates related to the current manuscript. M. G. reports grants from CDC, Westat, and Vanderbilt University Medical Center and participation on the Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics Infectious Diseases and Immunization Committee as co-chair. S. K. Y. and A. L. P. report a contract from Novavax, Inc, for unrelated studies. M. T. has consulted for Novavax and CSL Seqirus. A. C.-M. reports funding from the state of Florida for the Firefighter Cancer Initiative and a leadership role in the International Commission on Occupational Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Data availability . For questions about data availability, please contact the corresponding author.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>11</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39446477</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae491</ArticleId><ArticleId IdType="pii">7834998</ArticleId></ArticleIdList></PubmedData></PubmedArticle>